This Westminster conference will examine key issues for medicine regulation, looking at next steps for clinical trials and patient involvement.
Overall, key areas for discussion include:
- regulation - the MHRA’s Delivery Plan for 2021-23 - the evolving role and scope of the regulator - developing new approaches to regulation - partnerships.
- clinical trials - priorities for change following consultation - public involvement - efficiency - transparency - issues for ensuring patients are listened to and responded to as part of the process.
- innovation - regulatory support - developing frameworks to facilitate safe access to innovative products & new therapies - options for streamlining & fast-track approvals.
- wider priorities - evidence collection - improving health outcomes - engagement with the wider life sciences ecosystem - the UK’s international role.
Keynote sessions with Dr Glenn Wells, Chief Partnerships Officer, MHRA; Juliet Tizzard, Director of Policy and Partnerships, Health Research Authority; Dr Ali Hansford, Head of Regulatory Strategy Policy, ABPI; and Meindert Boysen, Director, Centre of Health Technology Evaluation, NICE.
The conference will be an opportunity for stakeholders to consider the issues alongside key policy officials who are due to attend from the DHSC; DIT; MHRA; GLD; OLS; and The Scottish Government.
There are no comments to display.
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!Register a new account
Already have an account? Sign in here.Sign In Now